Dr Reddys Laboratories announced positive topline results from its Phase 2b study of PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis. In the study,
PPC-06 met both co-primary endpoints i.e. PASI- 75 and IGA scores of O or 1 with at least a 2-point
reduction from baseline, after 24 weeks of oral treatment. The detailed safety and efficacy data from the
study will be presented in future dermatology conferences.
"Given the positive clinical data in this study, PPC-06 may have a potential to serve as an important therapeutic option for psoriasis patients in a market with limited oral treatments. We thank all the patients, investigators and study staff whose ongoing participation helped us achieve this target." said Sagar Munjal, MD, MS, Chief Medical Officer Promius Pharma/VP Clinical Development & Medical Affairs.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
